Next Article in Journal
In Vitro Autonomous Construction of the Flagellar Axial Structure in Inverted Membrane Vesicles
Previous Article in Journal
Improved Pullulan Production and Process Optimization Using Novel GA–ANN and GA–ANFIS Hybrid Statistical Tools
Open AccessConcept Paper

Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease

1
Clinic for Cardiology, University Medical Center Eppendorf, 20246 Hamburg, Germany
2
German Center for Cardiovascular Research (DZHK), Partner site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany
3
Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele Pisana, 00163 Rome, Italy
4
Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00163 Rome, Italy
5
INSERM, U1219 Bordeaux Population Health research center, University of Bordeaux, 33076 Bordeaux, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomolecules 2020, 10(1), 125; https://doi.org/10.3390/biom10010125
Received: 6 December 2019 / Revised: 3 January 2020 / Accepted: 9 January 2020 / Published: 11 January 2020
Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up to two-thirds of these patients exhibit symptoms suggestive for MI within 12 months prior to the acute MI event. An early identification of these at-risk subjects is necessary to manage an early and efficient treatment during the ischemic phase. The aim of the PRecision MEDicine in Coronary Artery Disease (PREMED-CAD) consortium is to apply a system medicine approach towards studying and identifying an ischemia specific ‘biomarker signature’ that improves the identification of individuals ‘at-risk’ for acute MI. The consortium will take an interdisciplinary and translational approach integrating knowledge from CAD epidemiology, imaging, bioinformatics, statistics and molecular biology, as well as existing phenotypic, blood-based and clinical biomarker data of distinct CAD and subclinical MI phenotypes. This biomarker signature will be validated through atherosclerosis-prone mouse models and human cohorts. The validated signature will be translated in a real-world clinical setting using an ongoing clinical trial comprising patients with subclinical ischemia. The aim of the knowledge obtained from this project is to aid in early MI detection and reduce the mortality and morbidity rate in these at-risk MI individuals. View Full-Text
Keywords: PREMED-CAD; precision medicine; biomarker; coronary artery disease; myocardial infarction; clinical trial; ischemia; at-risk PREMED-CAD; precision medicine; biomarker; coronary artery disease; myocardial infarction; clinical trial; ischemia; at-risk
Show Figures

Figure 1

MDPI and ACS Style

Shrivastava, A.; Marzolla, V.; Weidmann, H.; Caprio, M.; Tregouet, D.-A.; Zeller, T.; Karakas, M. Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease. Biomolecules 2020, 10, 125.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop